42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM)

Authors :: Rainer Kimmig
M.A. Ströhlein
Pauline Wimberger
H. Sommer
A.N. Makhson
M.R. Lichinitser
Alexander Burges
V.A. Gorbounova
Jacobus Pfisterer
B Schmalfeldt
Source :: European Journal of Cancer Supplements. 1:S17
Publication Year :: 2003
Publisher :: Elsevier BV, 2003.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bispecific antibody
business.industry
Anti cd3
medicine.disease
Phase i study
Internal medicine
Ascites
medicine
medicine.symptom
business
Ovarian cancer

Tools